Sign up Australia
Proactive Investors - Run By Investors For Investors

Viralytics anti-cancer drug achieves trial success in U.S.

Viralytics anti-cancer drug achieves trial success in U.S.

Viralytics Limited (ASX:VLA) is reaching milestones at a Phase 2 clinical trial of its CAVATAK anti-cancer drug in the treatment of late stage melanoma patients.

The Phase 2 trial at 11 U.S. sites is to investigate safety and efficacy of intra-tumoral CAVATAK injection in 54 patients with late stage malignant melanoma.

The primary endpoint of the study was to have 10 from 54 evaluable patients reporting immune-related Progression Free Survival at 6 months, which was achieved in September after only 30 evaluable patients, representing an irPFS rate of 33%.

Another key performance measure is the one-year survival following initiation of treatment with CAVATAK. Currently, 16 patients were evaluable by this measure with 9 alive at the 1 year endpoint, a success rate of 56%.

To put that into perspective, the mean one-year overall survival rate based on a review of 42 Phase 2 melanoma trials in patients treated with a variety of agents is 25.5%.

Viralytic's aim is to commence a randomised Phase 2 trial in melanoma patients in the late 2014. Strong recent recruitment rates indicate final patient enrolment by the end of this year.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full VLA profile View Profile

Viralytics Timeline

Newswire
December 10 2015

Related Articles

1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards
pipette and petri dish
June 20 2018
As well as developing its lead compound, Silence has also been busy taking its larger rivals to court over alleged patent infringements
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use